TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14626333

Group type: EXPERIMENTAL
Intervention: School-based delivery of inhaled corticosteroids (ICS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Home-based delivery of inhaled corticosteroids (ICS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Home-based delivery of inhaled corticosteroids (ICS) with school-based asthma education
Number of subjects: 50

Group type: COMPARATOR
Intervention: Community standard of care (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All treatment groups (combined)
Number of subjects: 50
Study: 10768961

Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate vaccine
Number of subjects: 106

Group type: COMPARATOR
Intervention: Meningococcal A/C polysaccharide vaccine
Number of subjects: 106
Study: 9494585

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 23
Study: 8443036

Group type: EXPERIMENTAL
Intervention: Capsaicin (50 nmol) applied to the human nasal mucosa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle applied to the contralateral nostril
Number of subjects: 0
Study: 3538945

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg three times daily)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ketanserin (after initial treatment with placebo)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (after initial treatment with ketanserin)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (in crossover treatment)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ketanserin (in crossover treatment)
Number of subjects: 82
Study: 31347430

Group type: EXPERIMENTAL
Intervention: Aspirin 81 to 200 mg plus cilostazol 200 mg (dual group)
Number of subjects: 1201

Group type: COMPARATOR
Intervention: Aspirin 81 to 200 mg (aspirin group)
Number of subjects: 1201
Study: 30205371

Group type: EXPERIMENTAL
Intervention: 1 L peripheral intravenous nutrition, 700 kcal
Number of subjects: 80

Group type: COMPARATOR
Intervention: 1 L isotonic electrolyte solution
Number of subjects: 80
Study: 27044959

Group type: EXPERIMENTAL
Intervention: Novel multidimensional intervention aimed at improving patient-provider communication.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Existing intervention focused on changing patients' behaviors.
Number of subjects: 300
Study: 24337154

Group type: EXPERIMENTAL
Intervention: Intralipid infusion (48 h, 30 ml/h)
Number of subjects: 12
Study: 22134012

Group type: EXPERIMENTAL
Intervention: WHO I (Ethanol 80% vol/vol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WHO II (Isopropanol 75% vol/vol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WHO I and WHO II with increased alcohol concentrations (80% wt/wt and 75% wt/wt)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference procedure 'R' (2 × 3 mL 60% vol/vol isopropanol for 2 × 30 seconds)
Number of subjects: 0
Study: 19832918

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (H(2)O(2); 0.013% H(2)O(2)/0.004% glycerol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo without H(2)O(2)
Number of subjects: 40
Study: 17197302

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard surgical approach
Number of subjects: 80
Study: 15860854

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m(2)) plus docetaxel (75 mg/m(2)) IV every 3 weeks (AD)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m(2)) plus cyclophosphamide (600 mg/m(2)) IV every 3 weeks (AC)
Number of subjects: 363
Study: 11914161

Group type: EXPERIMENTAL
Intervention: Extended structured recall and management system involving patients and clinical management prompts based on evidence-based guidelines.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard care (control group not explicitly mentioned but implied).
Number of subjects: 61
Study: 10190766

Group type: EXPERIMENTAL
Intervention: Ferrous-glycine-sulfate (200 mg elemental iron daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Iron and Placebo)
Number of subjects: 0
Study: 7787913

Group type: EXPERIMENTAL
Intervention: Pink tape
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Clear tape
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Butterfly tape
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Duodenal tubes
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Standard sump tubes
Number of subjects: 103
Study: 2085988

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FT, 3 g)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cotrimoxazole (CTX, 960 mg, 3 times daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cotrimoxazole (CTX)
Number of subjects: 36
Study: 479908

Group type: EXPERIMENTAL
Intervention: Combined histamine H1 and H2 antagonist treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 15
Study: 31371364

Group type: EXPERIMENTAL
Intervention: Computer-guided glucose management protocol
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine glycemic monitoring approach
Number of subjects: 66
Study: 28856906

Group type: EXPERIMENTAL
Intervention: P169 supplementation at a rate of 1×10^11 cfu/head/d
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control diet (n=3)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: P169 supplementation
Number of subjects: 7
Study: 24838423

Group type: EXPERIMENTAL
Intervention: 23G needle
Number of subjects: 119

Group type: COMPARATOR
Intervention: 25G needle
Number of subjects: 119
Study: 24173486

Group type: EXPERIMENTAL
Intervention: Standard illustrated discharge cards
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (no cards)
Number of subjects: 228
Study: 21371381

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 48
Study: 19521070

Group type: EXPERIMENTAL
Intervention: paricalcitol 1 micro/day
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: paricalcitol 2 microg/day
Number of subjects: 281

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 281
Study: 17910230

Group type: EXPERIMENTAL
Intervention: SE Bond Cuspal coverage restorations
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prime&Bond NT Cuspal coverage restorations
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cuspal coverage restorations (SE and PB)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Increased thickness in bonding agent in Class I restorations
Number of subjects: 72

Group type: COMPARATOR
Intervention: Bulk‐filled direct resin composite Cuspal coverage restorations
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Internal adaptation of Cuspal coverage SE Bond/Clearfil AP‐X restorations
Number of subjects: 72
Study: 15061249

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 552
Study: 11159234

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.01 microg. kg(‐1). min(‐1) to 0.17 microg. kg(‐1). min(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study: 9491827

Group type: EXPERIMENTAL
Intervention: Loratadine-pseudoephedrine (L + PS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 40
Study: 7936257

Group type: EXPERIMENTAL
Intervention: Protocol for treatment of acute stroke including a critical path for nursing care, an algorithm for emergency department care, and suggested admission orders for physicians.
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Protocol for treatment of acute stroke
Number of subjects: 390
Study: 6099707

Group type: EXPERIMENTAL
Intervention: High-dose intravenous cyclophosphamide
Number of subjects: 0
Study: 31248746

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including an online tool, meet-and-greet sessions, and research assistants.
Number of subjects: 5255
Study: 30369307

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 21105

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study: 27452936

Group type: EXPERIMENTAL
Intervention: 80% FiO2
Number of subjects: 85

Group type: COMPARATOR
Intervention: 30% FiO2
Number of subjects: 85
Study: 24528934

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (Ozurdex)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Macular grid laser
Number of subjects: 50
Study: 22324949

Group type: EXPERIMENTAL
Intervention: Diacerein 50 mg once daily for the first month and twice daily for the next 2 months with diclofenac sodium 75 mg once daily
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo with diclofenac sodium 75 mg once daily
Number of subjects: 74
Study: 19946814

Group type: EXPERIMENTAL
Intervention: Randomization at the patient level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing the number of measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding a covariate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25% drop-out rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small sample sizes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Larger sample sizes
Number of subjects: 0
Study: 17091024

Group type: EXPERIMENTAL
Intervention: Sequential estradiol‐norethisterone acetate regimen for 3 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Continued HT for 6 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HT
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 100
Study: 17683453

Group type: EXPERIMENTAL
Intervention: Audiovisual speech perception
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lipreading ability
Number of subjects: 37

Group type: COMPARATOR
Intervention: Audiovisual condition
Number of subjects: 37
Study: 15000640

Group type: EXPERIMENTAL
Intervention: Incremental placement technique using Single Bond + Filtek Z250
Number of subjects: 6

Group type: COMPARATOR
Intervention: Bulk placement technique using Single Bond + Filtek P60
Number of subjects: 6
Study: 10885414

Group type: EXPERIMENTAL
Intervention: AutoSet (autoadjusting nasal CPAP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional nasal CPAP (manual mode)
Number of subjects: 10
Study: 8781301

Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate (VS) 50 mg twice daily orally for 4 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 8
Study: 1352496

Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 53

Group type: COMPARATOR
Intervention: 20 mg nitrendipine
Number of subjects: 53
Study: 6496393

Group type: EXPERIMENTAL
Intervention: Animal protein diet (55% beef protein)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Plant protein diet
Number of subjects: 8
Study: 31563148

Group type: EXPERIMENTAL
Intervention: 1.3% sodium hypochlorite
Number of subjects: 308

Group type: COMPARATOR
Intervention: 5.25% sodium hypochlorite
Number of subjects: 308
Study: 31601569

Group type: EXPERIMENTAL
Intervention: hu14.18K322A with induction chemotherapy
Number of subjects: 42
Study: 28217883

Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed Loading (DL)
Number of subjects: 0
Study: 26177630

Group type: EXPERIMENTAL
Intervention: CAF + CTG + PRF
Number of subjects: 40

Group type: COMPARATOR
Intervention: CAF + CTG
Number of subjects: 40
Study: 23706094

Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention including educational weight loss workbook, pedometer, elastic Thera-bands® for strength training, and behavioral telephone-based coaching.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care including educational weight loss workbook and pedometer for self-monitoring of physical activity.
Number of subjects: 0
Study: 21737832

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) applied during arthroscopic rotator cuff repair
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional repair (without PRP)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PRP group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Overall comparison of PRP vs conventional repair
Number of subjects: 42
Study: 19491556

Group type: EXPERIMENTAL
Intervention: Extended-release guaifenesin/pseudoephedrine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 0
Study: 16770976

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) injections plus standard clinical care
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard clinical care alone
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Blinded LMWH group
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Unblinded LMWH group
Number of subjects: 138

Group type: COMPARATOR
Intervention: Blinded placebo arm
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard care arm
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: LMWH arms
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control arms
Number of subjects: 138
Study: 14763475

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 30
Study: 11480653

Group type: EXPERIMENTAL
Intervention: Titratable oral appliance in mandibular position MAX67
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Titratable oral appliance in mandibular position MAX
Number of subjects: 10

Group type: COMPARATOR
Intervention: Titratable oral appliance in mandibular position RP
Number of subjects: 10
Study: 9428829

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate (400 mg/day for 14 days followed by 76 days of elemental calcium 500 mg/day)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Calcium only (placebo)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate
Number of subjects: 193
Study: 8512094

Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Isoflurane/nitrous oxide
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Fentanyl/nitrous oxide
Number of subjects: 121
Study: 3730231

Group type: EXPERIMENTAL
Intervention: Halothane 2.1 MAC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Halothane 1.2 MAC
Number of subjects: 0
Study: 29848613

Group type: EXPERIMENTAL
Intervention: Variants of uncertain significance
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Possibly pathogenic result
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Single uncertain result
Number of subjects: 289
Study: 27736851

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux en Y gastric bypass (LRYGB)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both LSG and LRYGB
Number of subjects: 114
Study: 25516885

Group type: EXPERIMENTAL
Intervention: Nanohybrid resin composite (Excite/Tetric EvoCeram)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional hybrid resin composite (Excite/Tetric Ceram)
Number of subjects: 52
Study: 22588236

Group type: EXPERIMENTAL
Intervention: Myringoplasty with cortical mastoidectomy (Group A)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Myringoplasty only (Group B)
Number of subjects: 320
Study: 20433700

Group type: EXPERIMENTAL
Intervention: ProActive intervention (physical activity promotion)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Baseline demographic, clinical, psychosocial and behavioural variables
Number of subjects: 321
Study: 18698246

Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL) photodynamic therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (lesion-specific treatment, 83% cryotherapy)
Number of subjects: 81
Study: 15713351

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 21

Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 21
Study: 12075764

Group type: EXPERIMENTAL
Intervention: Oral, killed enterotoxigenic Escherichia coli plus cholera toxin B-subunit vaccine
Number of subjects: 64
Study: 9524014

Group type: EXPERIMENTAL
Intervention: cilazapril 2 x 2.5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 7706153

Group type: EXPERIMENTAL
Intervention: constructed‐response interactive videodisc instruction
Number of subjects: 101

Group type: COMPARATOR
Intervention: click‐to‐continue or passive viewing formats
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: constructed answers
Number of subjects: 101
Study: 2748470

Group type: EXPERIMENTAL
Intervention: Diapers with absorbent polymer
Number of subjects: 150

Group type: COMPARATOR
Intervention: Fluff diapers
Number of subjects: 150
Study: 200357

Group type: EXPERIMENTAL
Intervention: Involved-field irradiation and further chemotherapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Prophylactic whole-brain irradiation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 31
Study: 31811839

Group type: EXPERIMENTAL
Intervention: 3mg vaginal dinoprostone
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 30591470

Group type: EXPERIMENTAL
Intervention: Data accuracy assessment from the Regional Head and Neck Register
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Follow-up data assessment from the Regional Head and Neck Register
Number of subjects: 73
Study: 27503233

Group type: EXPERIMENTAL
Intervention: Homozygous secretors (SeSe)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Non-secretors (sese)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Fungal, viral and non‐dominant bacterial components of the microbiome
Number of subjects: 112
Study: 25555163

Group type: EXPERIMENTAL
Intervention: 20% 1RM blood-flow restriction at 40% pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30% 1RM blood-flow restriction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20% 1RM blood-flow restriction at 50% pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20% 1RM blood-flow restriction at 60% pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-load condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20% 1RM to failure
Number of subjects: 0
Study: 23620429

Group type: EXPERIMENTAL
Intervention: Digital color grading of fundus photographs
Number of subjects: 4203

Group type: COMPARATOR
Intervention: Historical film-based images
Number of subjects: 4203

Group type: EXPERIMENTAL
Intervention: AREDS2-AREDS concordance for temporal drift
Number of subjects: 4203
Study: 21679357

Group type: EXPERIMENTAL
Intervention: Supported speed treadmill training exercise program (SSTTEP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Exercise (strengthening)
Number of subjects: 26
Study: 19539101

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg BID
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 16931867

Group type: EXPERIMENTAL
Intervention: Glucose+fructose solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sucrose solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 0
Study: 15383183

Group type: EXPERIMENTAL
Intervention: Quetiapine (300.5 mg/day mean dose, maximum 686.0 mg/day)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 426
Study: 11023137

Group type: EXPERIMENTAL
Intervention: High-fiber (HF) diet
Number of subjects: 63

Group type: COMPARATOR
Intervention: Low-fiber (LF) diet
Number of subjects: 63
Study: 9012298

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) infusion at 1.5 micrograms/kg/min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 10
Study: 1415377

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) treatment at Hb 9 g/dl
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) treatment at Hb 12 g/dl
Number of subjects: 12
Study: 3892745

Group type: COMPARATOR
Intervention: Stapled anastomoses and skin closures
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Nonstapled anastomoses
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sutured anastomoses with sutured skin closure
Number of subjects: 69

Group type: COMPARATOR
Intervention: Stapled skin closure
Number of subjects: 69

Group type: COMPARATOR
Intervention: Stapled closure in guinea pig model
Number of subjects: 69
Study: 30115264

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (PreOp™; Nutricia, Erlangen, Germany)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard preoperative fasting
Number of subjects: 120
Study: 27865182

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800mg/day with pitavastatin 2mg/day
Number of subjects: 241

Group type: COMPARATOR
Intervention: Statin alone (control group)
Number of subjects: 241
Study: 24788580

Group type: EXPERIMENTAL
Intervention: Caregiver-mediated home-based intervention (CHI)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (therapist visits without intervention)
Number of subjects: 51
Study: 23219638

Group type: EXPERIMENTAL
Intervention: Laerdal circuit with PEEP 7.5 cmH(2)O
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mapleson‐C circuit with PEEP 7.5 cmH(2)O
Number of subjects: 15

Group type: COMPARATOR
Intervention: Laerdal circuit
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mapleson‐C circuit
Number of subjects: 15
Study: 21576129

Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg bid
Number of subjects: 4628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4628
Study: 17949799

Group type: EXPERIMENTAL
Intervention: i.v. pegylated liposomal doxorubicin (PLD) (30 mg/m2) plus i.v. carboplatin (AUC=5 mg/mL min) once every 4 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: i.v. carboplatin alone (AUC=5 mg/mL min) once every 4 weeks
Number of subjects: 61
Study: 16815121

Group type: EXPERIMENTAL
Intervention: Starch-based thickeners
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Gum-based thickeners
Number of subjects: 5

Group type: COMPARATOR
Intervention: Original beverages
Number of subjects: 5
Study: 14550869

Group type: EXPERIMENTAL
Intervention: Cisapride (test)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propulsid (reference)
Number of subjects: 12